ClarkA, JitM, Warren-GashC, et al.How many are at increased risk of severe COVID-19 disease? Rapid global, regional and national estimates for 2020. medRxiv, 2020. DOI: 10.1101/2020.04.18.20064774.
2.
XuZ, ZhangC, WangFS. COVID-19 in people with HIV. Lancet HIV, 2020; 7:e524–e526.
3.
LaurenceJ. Why aren't people living with HIV at higher risk for developing severe coronavirus disease 2019 (COVID-19)?. AIDS Patient Care STDS, 2020; 34:247–248.
4.
JohnstonR.The first 6 months of HIV-SARS-CoV-2 coinfection: Outcomes for 6947 individuals. Curr Opin HIV AIDS, 2020. DOI: 10.1097/COH0000000000000654.
5.
MillettGA, HonermannB, JonesA, et al.White counties stand apart: The primacy of residential segregation in COVID-19 and HIV diagnoses. AIDS Patient Care STDS, 2020; 34:417–424.
6.
LodgeW, 2nd, KuchukhidzeS. COVID-19, HIV, and migrant workers: The double burden of the two viruses. AIDS Patient Care STDS, 2020; 34:249–250.
7.
ShahASV, StelzleD, LeeKK, et al.Global burden of atherosclerotic cardiovascular disease in people living with HIV: Systematic review and meta-analysis. Circulation, 2018; 138:1100–1112.
8.
LaurenceJ, ElhadadS, AhamedJ. HIV-associated cardiovascular disease: Importance of platelet activation and cardiac fibrosis in the setting of specific antiretroviral therapies. Open Heart, 2018; 5:e000823.
9.
BignaJJ, KenneAM, AsangbehSL, SibetcheuAT. Prevalence of chronic obstructive pulmonary disease in the global population with HIV: A systematic review and meta-analysis. Lancet Global Health, 2018; 6:e193–e202.
10.
SmithCJ, RyomL, WeberR, et al.Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): A multicohort collaboration. Lancet, 2014; 384:241–248.
11.
Van EppsP, KalayjianRC. Human immunodeficiency virus and aging in the era of effective antiretroviral therapy. Infect Dis Clin North Am, 2017; 31:791–810.
12.
GreenhalghT, KnightM, A'CourtC, et al.Management of post-acute covid-19 in primary care. BMJ (Clin Res ed.), 2020; 370:m3026.
13.
TenfordeMW, KimSS, LindsellCJ, et al.Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a Multistate Health Care Systems Network—United States, March–June 2020. MMWR Morb Mortal Wkly Rep, 2020; 69:993–998.
14.
Tung-ChenY, Blanco-AlonsoS, Antón-HuguetB, et al.[Persistent chest pain after resolution of coronavirus 2019 disease (COVID-19)]. Semergen, 2020; 46(Suppl. 1):88–90.
15.
Carfì. A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA, 2020; 324:603–605.
16.
PuntmannVO, CarerjML, WietersI, et al.Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19). JAMA Cardiol, 2020; 5:1265–1273.
17.
MandalS, BarnettJ, BrillSE, et al. “Long-COVID”: A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax, 2020. DOI: 10.1136/thoraxjnl-2020-215818.
18.
KingstoneT, TaylorAK, O'DonnellCA, et al.Finding the “right” GP: A qualitative study of the experiences of people with long-COVID. BJGP Open, 2020. DOI: 10.3399/bjgpopen20X101143.
19.
CostiniukCT, JenabianMA. HIV reservoir dynamics in the face of highly active antiretroviral therapy. AIDS Patient Care STDS, 2015; 29:55–68.
20.
SenguptaS, SilicianoRF. Targeting the latent reservoir for HIV-1. Immunity, 2018; 48:872–895.
21.
YuklSA, KaiserP, KimP, et al.HIV latency in isolated patient CD4(+) T cells may be due to blocks in HIV transcriptional elongation, completion, and splicing. Sci Transl Med, 2018; 10:eaap9927.
22.
KlattNR, ChomontN, DouekDC, DeeksSG. Immune activation and HIV persistence: Implications for curative approaches to HIV infection. Immunol Rev, 2013; 254:326–342.
23.
RuggieroA, De SpiegelaereW, Cozzi-LepriA, et al.During stably suppressive antiretroviral therapy integrated HIV-1 DNA load in peripheral blood is associated with the frequency of CD8 cells expressing HLA-DR/DP/DQ. EBioMedicine, 2015; 2:1153–1159.
24.
HuR, YanH, LiuM, et al.Virologic and immunologic outcomes for HIV patients with coronavirus disease 2019. J Acquir Immune Defic Syndr, 2020. DOI: 10.1097/QA1.0000000000002540.
25.
KeeneC, Mohr-HollandE, CassidyT, et al.How COVID-19 could benefit tuberculosis and HIV services in South Africa. Lancet Resp Med, 2020; 8:844–846.
26.
HoganAB, JewellBL, Sherrard-SmithE, et al.Potential impact of the COVID-19 pandemic on HIV, tuberculosis, and malaria in low-income and middle-income countries: A modelling study. Lancet Global Health, 2020. DOI: 10.1016/S2214-109X(20)30288-6.
27.
SandsP.HIV, tuberculosis, and malaria: How can the impact of COVID-19 be minimised? Lancet Global Health, 2020. DOI: 10.1016/S2214-109X(20)30317-X.
28.
BuchbinderSP, McElrathMJ, DieffenbachC, CoreyL. Use of adenovirus type-5 vectored vaccines: A cautionary tale. Lancet, 2020; 396:e68–e69.
29.
YamamotoS, SaitoM, NagaiE, et al.Antibody response to SARS-CoV-2 in people living with HIV. J Microbiol Immunol Infect, 2020. DOI: 10.1016/jmii.2020.09.005.
30.
SharovKS.HIV/SARS-CoV-2 co-infection: T cell profile, cytokine dynamics and role of exhausted lymphocytes. Int J Infect Dis, 2020. DOI: 10.1016/j.ijid.2020.10.049.
31.
SimonS, LabarriereN. PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?. Oncoimmunology, 2017; 7:e1364828.
32.
DongE, DuH, GardnerL. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis, 2020; 20:533–534.
